Venetoclax

Last updated

Venetoclax
Venetoclax.svg
Venetoclax.png
Clinical data
Pronunciation /vɛˈnɛtəklæks/
ve-NE-tə-klaks
Trade names Venclexta, Venclyxto
Other namesGDC-0199, ABT-199, RG-7601
AHFS/Drugs.com Monograph
MedlinePlus a616028
License data
Pregnancy
category
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding >99.9% [7]
Metabolism Liver (CYP3A4, CYP3A5)
Elimination half-life ~26 hours
Excretion Feces (>99.9%; 20.8% as unchanged venetoclax)
Identifiers
  • 4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.254.611 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C45H50ClN7O7S
Molar mass 868.45 g·mol−1
3D model (JSmol)
  • CC1(CCC(=C(C1)c2ccc(cc2)Cl)CN3CCN(CC3)c4ccc(c(c4)Oc5cc6cc[nH]c6nc5)C(=O)NS(=O)(=O)c7ccc(c(c7)[N+](=O)[O-])NCC8CCOCC8)C
  • InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54) COPY
  • Key:LQBVNQSMGBZMKD-UHFFFAOYSA-N

Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML). [7] [8]

Contents

The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness. [8]

Venetoclax attaches to a protein called Bcl-2. [8] This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. [8] By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease. [8]

Medical uses

CLL/SLL

In the US, venetoclax is indicated for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [7] [9] Indication does not depend on mutation status (e. g. 17p deletion, IGHV mutation, 12+).

In the EU, venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adults who are unsuitable for or have failed a B cell receptor pathway inhibitor and for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adults who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor. [8]

Other types of leukemia

Acute myeloid leukemia

Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used. [7]

A retrospective study examined the characteristics and outcomes of 83 AML patients, aged ≥75 years old, by comparing two periods: 2016-2018 (36 patients , before Venetoclax approval) and 2019-2021 (47 patients, following Venetoclax approval): It was found that during 2019-2021 more ≥75 patients received anti-AML treatment than in 2016-2018 (87.2% vs. 55.6%, respectively), and different outcomes were significantly improved in 2019-2021 comparing 2016-2018, for example: complete remission (44.7% vs. 19.4%, respectively), 30 day mortality rate (12.8% vs. 38.9%), 1-year overall survival (29.8% vs. 11.1%), 1-year relapse free survival (57.1% vs. 14.3%) and 1-year event free survival (25.5% vs. 2.8%). [10]

Side effects

Common side effects of venetoclax include neutropenia (low white blood cell count), nausea, anemia, diarrhea, upper respiratory tract infection, fatigue, and thrombocytopenia (low platelet count). Major side effects include tumor lysis syndrome and severe neutropenia. Additionally, this drug may cause fertility problems in males. [7]

Pharmacology

Mechanism of action

Venetoclax is a BH3-mimetic. [11] Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has been linked to increased resistance to chemotherapy. [12]

Pharmacokinetics

The maximum plasma concentration achieved after oral administration occurred 5–8 hours after dose. [7] Steady state maximum concentration with low-fat meal conditions at the 400 mg once daily dose was found to be 2.1 ± 1.1 μg/mL. It is recommended that venetoclax be administered with a meal. [7]

The apparent volume of distribution for venetoclax is approximately 256–321 L. It is highly bound to human plasma protein. Within a concentration range of 1-30 μM (0.87-26 μg/mL), the fraction unbound in plasma was less than 0.01. [7]

Venetoclax is metabolized by CYP3A4/5 as proven by in-vitro studies. [7] Those using the drug should not consume grapefruit products because they contain CYP3A inhibitors. [7] Additionally, while using venetoclax it is not recommended to use other drugs which contain CYP3A inhibitors (i.e.: erythromycin, ciprofloxacin, diltiazem, dronedarone, fluconazole, verapamil). [7] Venetoclax is excreted from the body via the fecal route. [7]

History

In 2015, the United States Food and Drug Administration (FDA) granted the breakthrough therapy designation to venetoclax for people with CLL or SLL who have relapsed, become intolerant to, or refractory to previous treatment.[ medical citation needed ]

In April 2016, the FDA approved venetoclax for use in those with CLL who have 17p deletion (deletion located on the chromosome 17 short arm) and who have been treated with at least one prior therapy. [13] [14] [15] [16] Based on overall response rate, the indication was approved under accelerated FDA approval. [7]

The efficacy of venetoclax was tested in a single-arm clinical trial of 106 participants with CLL who have a 17p deletion and who had received at least one prior therapy. [14] Trial participants took venetoclax orally every day, beginning with 20 mg and increasing over a five-week period to 400 mg. [14] Results showed that 80 percent of trial participants experienced a complete or partial remission of their cancer. [14] The trial was conducted in the US, Canada, France, Germany, Poland, the United Kingdom, and Australia. [16]

The application for venetoclax was granted priority review and accelerated approval along with breakthrough therapy designation and orphan drug designation. [14]

Venetoclax was approved for use in the European Union in December 2016. [8]

In June 2018, the FDA granted regular approval to venetoclax for people with CLL or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. [17]

Approval was based on MURANO (NCT02005471), a randomized (1:1), multicenter, open-label trial of venetoclax with rituximab (VEN+R) versus bendamustine with rituximab (B+R) in 389 participants with CLL who had received at least one prior line of therapy. [17] Participants in the VEN+R arm completed a 5-week ramp-up venetoclax schedule and then received venetoclax 400 mg once daily for 24 months measured from the rituximab start date. [17] Rituximab was initiated after venetoclax ramp-up and given for 6 cycles (375 mg/m2 intravenously on cycle 1 day 1 and 500 mg/m2 intravenously on day 1 of cycles 2–6, with a 28-day cycle length). [17] The comparator arm received 6 cycles of B+R (bendamustine 70 mg/m2 on days 1 and 2 of each 28-day cycle and rituximab at the above described dose and schedule). [17]

The application for venetoclax in combination with rituximab was granted priority review along with a breakthrough therapy designation. [17]

In November 2018, in the United States, venetoclax was approved in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. [18]

Accelerated approval was based on two open-label non-randomized trials in participants with newly diagnosed AML who were >= 75 years of age or had comorbidities that precluded the use of intensive induction chemotherapy. [18] Efficacy was established based on the rate of complete remission (CR) and CR duration. [18]

Study M14-358 (NCT02203773) was a non-randomized, open-label clinical trial of venetoclax in combination with azacitidine (n=67) or decitabine (n=13) in newly diagnosed participants with AML. [18] In combination with azacitidine, 25 participants achieved a CR (37%, 95% CI: 26, 50) with a median observed time in remission of 5.5 months (range: 0.4–30 months). [18] In combination with decitabine, 7 participants achieved a CR (54%, 95% CI: 25, 81) with a median observed time in remission of 4.7 months (range: 1.0–18 months). [18] The observed time in remission is the time from start of CR to data cut-off date or relapse from CR. [18] In a phase 3 study of azacitidine and venetoclax in untreated acute myeloid leukemia not eligible for standard induction chemotherapy, the addition of venetoclax to azacitidine resulted in an improvement in median overall survival (14.7 months versus 9.6 months) and improved complete remission rates. [19]

Study M14-387 (NCT02287233) was a non-randomized, open-label trial of venetoclax in combination with low-dose cytarabine (n=61) in newly diagnosed participants with AML, including participants with previous exposure to a hypomethylating agent for an antecedent hematologic disorder. [18] In combination with low-dose cytarabine, 13 participants achieved a CR (21%, 95% CI: 12, 34) with a median observed time in remission of 6 months (range: 0.03–25 months). [18]

In May 2019, the label was extended by accelerated approval to include all adults with CLL/SLL disregarding prior treatment or mutation status. [9]

Approval was based on CLL14 (NCT02242942), a randomized (1:1), multicenter, open label, actively controlled trial of venetoclax in combination with obinutuzumab (VEN+G) versus obinutuzumab in combination with chlorambucil (GClb) in 432 participants with previously untreated CLL with coexisting medical conditions. [9]

The major efficacy outcome was progression-free survival (PFS) assessed by an independent review committee. [9] The trial demonstrated a statistically significant improvement in PFS for participants who received VEN+G compared with those who received GClb (HR 0.33; 95% CI: 0.22, 0.51; p<0.0001). [9] Median PFS was not reached in either arm after a median follow-up duration of 28 months. [9] The overall response rate was 85% in VEN+G arm compared to 71% in GClb arm, p=0.0007. [9] The trial also demonstrated statistically significant improvements in rates of minimal residual disease negativity (less than one CLL cell per 104 leukocytes) in bone marrow and peripheral blood. [9] Overall survival data were not mature at this analysis. [9]

The FDA used the Real-Time Oncology Review and Assessment Aid Pilot Program for this application and granted priority review as well as orphan drug and breakthrough therapy designations. [9] Approval was granted 3.7 months ahead of the Prescription Drug User Fee Act (PDUFA) date. [9]

Society and culture

AbbVie Inc. manufactures Venclexta. [14] It is marketed by both Abbvie and Genentech USA, which is a member of the Roche Group. [14] AbbVie and Genentech are both commercializing the drug within the United States, but only AbbVie has rights to do so outside of the U.S. [20]

According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion. [21] : 3, 7–8  Competition as well as potential for combination is expected from other drugs such as ibrutinib and idelalisib, both of which were also approved in 2014 to treat CLL. [21] : 7–8  [22]

Venetoclax is patented by AbbVie Inc. [23] [24] [25] [26]

Research

As of 2016, venetoclax had been tested to treat other hematological cancers, including non-Hodgkin's lymphoma, multiple myeloma, diffuse large B-cell lymphoma and follicular lymphoma. [21] : 7–8 

On 13 June 2020 at the European Hematology Association (EHA) annual congress, AbbVie and Roche announced the results of a Phase III trial that showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo. [27] [28] [29] Several trials have assessed the combination of venetoclax with intensive chemotherapy in younger AML patients. [30]

Related Research Articles

<span class="mw-page-title-main">Leukemia</span> Blood cancers forming in the bone marrow

Leukemia is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.

<span class="mw-page-title-main">Chronic lymphocytic leukemia</span> Bone marrow cancer in which lymphocytes are overproduced

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes. Early on, there are typically no symptoms. Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur. Enlargement of the spleen and low red blood cells (anemia) may also occur. It typically worsens gradually over years.

<span class="mw-page-title-main">Tumors of the hematopoietic and lymphoid tissues</span> Tumors that affect the blood, bone marrow, lymph, and lymphatic system

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

<span class="mw-page-title-main">Bcl-2</span> Protein found in humans

Bcl-2, encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins. BCL2 blocks programmed cell death (apoptosis) while other BCL2 family members can either inhibit or induce it. It was the first apoptosis regulator identified in any organism.

<span class="mw-page-title-main">Rituximab</span> Biopharmaceutical drug

Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion.

<span class="mw-page-title-main">Gemtuzumab ozogamicin</span> Pharmaceutical drug

Gemtuzumab ozogamicin, sold under the brand name Mylotarg®, is an antibody-drug conjugate that is used to treat acute myeloid leukemia (AML).

<span class="mw-page-title-main">Bruton's tyrosine kinase</span> Kinase that plays a role in B cell development

Bruton's tyrosine kinase, also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.

Richter's transformation (RT), also known as Richter's syndrome, is the conversion of chronic lymphocytic leukemia (CLL) or its variant, small lymphocytic lymphoma (SLL), into a new and more aggressively malignant disease. CLL is the circulation of malignant B lymphocytes with or without the infiltration of these cells into lymphatic or other tissues while SLL is the infiltration of these malignant B lymphocytes into lymphatic and/or other tissues with little or no circulation of these cells in the blood. CLL along with its SLL variant are grouped together in the term CLL/SLL.

<span class="mw-page-title-main">Mantle cell lymphoma</span> Type of blood cancer

Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, comprising about 6% of cases. It is named for the mantle zone of the lymph nodes where it develops. The term 'mantle cell lymphoma' was first adopted by Raffeld and Jaffe in 1991.

<span class="mw-page-title-main">Bendamustine</span> Chemical compound

Bendamustine, sold under the brand name Treanda among others, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.

<span class="mw-page-title-main">Blastic plasmacytoid dendritic cell neoplasm</span> Medical condition

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN constitutes 0.44% of all hematological malignancies.

<span class="mw-page-title-main">Phosphoinositide 3-kinase inhibitor</span>

Phosphoinositide 3-kinase inhibitors are a class of medical drugs that are mainly used to treat advanced cancers. They function by inhibiting one or more of the phosphoinositide 3-kinase (PI3K) enzymes, which are part of the PI3K/AKT/mTOR pathway. This signal pathway regulates cellular functions such as growth and survival. It is strictly regulated in healthy cells, but is always active in many cancer cells, allowing the cancer cells to better survive and multiply. PI3K inhibitors block the PI3K/AKT/mTOR pathway and thus slow down cancer growth. They are examples of a targeted therapy. While PI3K inhibitors are an effective treatment, they can have very severe side effects and are therefore only used if other treatments have failed or are not suitable.

<span class="mw-page-title-main">Ibrutinib</span> Medication used in cancer treatment

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Ibrutinib also binds to C-terminal Src Kinases. These are off-target receptors for the BTK inhibitor. Ibrutinib binds to these receptors and inhibits the kinase from promoting cell differentiation and growth. This leads to many different side effects like left atrial enlargement and atrial fibrillation during the treatment of Chronic Lymphocytic Leukemia.

<span class="mw-page-title-main">Idelalisib</span> Chemical compound

Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase. It was developed by Gilead Sciences. It is taken orally.

FCM, or FMC in the context of chemotherapy is an acronym for a chemotherapy regimen that is used in the treatment of indolent B cell non-Hodgkin's lymphomas. In combination with Rituximab, this regimen is called R-FCM or R-FMC, or FCM-R, FMC-R.

<span class="mw-page-title-main">Acalabrutinib</span> Chemical compound

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings.

<span class="mw-page-title-main">Duvelisib</span> PI3K inhibitor

Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. It is taken by mouth. It is a PI3 kinase inhibitor.

<span class="mw-page-title-main">Umbralisib</span> Chemical compound

Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.

BeiGene, Ltd. is a China-based drug developer. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

References

  1. ↑ "Venetoclax (Venclexta) Use During Pregnancy". Drugs.com. 29 May 2019. Retrieved 25 April 2020.
  2. ↑ "AusPAR: Venetoclax". Therapeutic Goods Administration (TGA). 26 April 2022. Retrieved 27 April 2022.
  3. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  4. ↑ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  5. ↑ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada . 14 March 2017. Retrieved 7 April 2024.
  6. ↑ "Venclyxto 10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 21 April 2020. Retrieved 25 April 2020.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Venclexta- venetoclax kit Venclexta- venetoclax tablet, film coated". DailyMed. 12 November 2019. Retrieved 25 April 2020.
  8. 1 2 3 4 5 6 7 8 "Venclyxto EPAR". European Medicines Agency (EMA). 21 December 2016. Retrieved 25 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. 1 2 3 4 5 6 7 8 9 10 11 "FDA approves venetoclax for CLL and SLL". U.S. Food and Drug Administration (FDA) (Press release). 15 May 2019. Retrieved 25 April 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  10. ↑ Moshe Y, Levi S, et al. (August 2023). "P560: Improvement in overall and relapse free survival of AML patients over the age of 75 since the approval of venetoclax in a real-world single center study". HemaSphere. 7(S3) (1): 89–98. doi:10.1097/01.HS9.0000969144.75498.e6. PMC   10428728 . PMID   27806433.
  11. ↑ Roberts AW, Huang D (January 2017). "Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies". Clinical Pharmacology and Therapeutics. 101 (1): 89–98. doi:10.1002/cpt.553. PMC   5657403 . PMID   27806433.
  12. ↑ "Center for Drug Evaluation and Research - Application 208573Orig1s000 - Division Director Summary Review" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 21 November 2016.
  13. ↑ "Venclexta Tablets". U.S. Food and Drug Administration (FDA). 19 May 2016. Retrieved 25 April 2020.
  14. 1 2 3 4 5 6 7 "FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality". U.S. Food and Drug Administration (FDA) (Press release). 11 April 2016. Retrieved 25 April 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  15. ↑ "Venetoclax (Venclexta) Tablets". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 25 April 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  16. 1 2 "Drug Trials Snapshot: Venclexta". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 25 April 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  17. 1 2 3 4 5 6 "FDA approves venetoclax for CLL or SLL, with or without 17p deletion, after one prior therapy". U.S. Food and Drug Administration (FDA) (Press release). 8 June 2018. Retrieved 25 April 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  18. 1 2 3 4 5 6 7 8 9 "FDA approves venetoclax in combination for AML in adults". U.S. Food and Drug Administration (FDA). 21 November 2018. Retrieved 25 April 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  19. ↑ DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. (August 2020). "Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia". The New England Journal of Medicine. 383 (7): 617–629. doi: 10.1056/NEJMoa2012971 . PMID   32786187.
  20. ↑ "Inside the development of Venclexta, AbbVie's new leukemia drug". BioPharma Dive. Retrieved 16 November 2016.
  21. 1 2 3 "Drugs to Watch 2016 - Market Insight Report" (PDF). Thomson Reuters . February 2016. Archived from the original (PDF) on 31 May 2021. Retrieved 13 February 2021.
  22. ↑ "Ibrutinib and Idelalisib Continue to Impress in CLL, May Eventually Replace Chemotherapy for Some Patients". OncLive. Retrieved 17 November 2016.
  23. ↑ "United States Patent: 9174982". patft.uspto.gov. Archived from the original on 11 October 2018. Retrieved 21 November 2016.
  24. ↑ "venetoclax". drugcentral.org. Retrieved 15 June 2020.
  25. ↑ "Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases - Patent US9174982 - PubChem". pubchem.ncbi.nlm.nih.gov. Retrieved 15 June 2020.
  26. ↑ "Venetoclax | US Patents | Expiry | Expiration | Dates". PharmaCompass.com. Retrieved 15 June 2020.
  27. ↑ "BRIEF-Roche Reports Positive Phase 3 Results For Venclexta/Venclyxto Combination In Acute Myeloid Leukaemia". Reuters. 13 June 2020. Archived from the original on 15 June 2020. Retrieved 15 June 2020.
  28. ↑ "EHA: AbbVie, Roche cement Venclexta's place in AML with survival win". FiercePharma. 13 June 2020. Retrieved 15 June 2020.
  29. ↑ "Venclexta/Venclyxto (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients". AbbVie. Retrieved 15 June 2020.
  30. ↑ Molica M, Perrone S, Federico V, Alati C, Molica S, Rossi M (December 2023). "Venetoclax: A Game Changer in the Treatment of Younger AML Patients?". Cancers. 16 (1): 73. doi: 10.3390/cancers16010073 . PMC   10778458 . PMID   38201501.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.